Duke University

University of Florida Research Foundation Inc

Other

The University of Texas System

Duane A Mitchell

John Howard Sampson

Michael D Gunn

Kristen A Batich

Catherine Flores

Maryam Rahman

Hassan Azari

Darell D Bigner

Amy Heimberger

Rolando Lovaton

Elias Sayour

The present disclosure provides methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI) in a subject and methods of treating a subject with an immune checkpoint inhibitor (ICI)-resistant tumor. The methods comprise administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Also provided are methods of increasing the number of activated plasmacytoid dendritic cells (pDCs) in a subject in need thereof, comprising administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Combination therapy with anti-PD-L1mAb. Related methods of treatment and methods of preparing a dendritic cell vaccine are additionally provided.

Methods of sensitizing tumors to treatment with immune checkpoint inhibitors

Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.

Methods, kits, and compositions for enhancing cellular therapy

The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Compositions, methods and kits for eliciting an immune response

The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.

Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer

Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.

Tetanus toxoid and CCL3 improve DC vaccines

The combination of adoptive cell therapy with CCR2 positive (CCR2) hematopoietic stem cell transplantation increases T cell activation and survival.

Growing community of inventors

Durham, NC, United States of America

Duane A Mitchell